- Home
- AMZE vs GDTC Comparison
AMZE vs GDTC Comparison
Compare AMZE & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | GDTC |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | Singapore |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMZE | GDTC |
|---|---|---|
| Price | $0.28 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 762.8K | 17.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6,741.66 | $5.37 |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.73 |
| 52 Week High | $11.76 | $3.68 |
Technical Indicators
Market Signals| Indicator | AMZE | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 49.75 |
| Support Level | $0.24 | $0.96 |
| Resistance Level | $0.41 | $1.25 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.67 | 83.82 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.